Pheton Holdings Limited (PTHL): Rasio rega marang dodolan

Tandha merek Pheton Holdings Ltd (PTHL)

Pheton Holdings Ltd (PTHL) is implementing specialized brachytherapy software through partnerships with Chinese clinics. The niche focus of the business is offset by strong patent protection, while its technological base in Asia facilitates the development of innovative IT solutions. The GURU.Markets platform presents this normalized P/S ratio for the company, where 27.50 determines the current value of the metric, allowing for an assessment of the asset's market value relative to its revenue.

PTHL: Multiplikator P/S Pheton Holdings Ltd 06.09.2024 - 16.01.2026

Rincian metrik lan analitis perusahaan Pheton Holdings Ltd (PTHL)

- data kapitalisasi bursa:
Analisis fundamental perusahaan:ftzy.com.cn (PTHL)
Produk merek Pheton

The P/S ratio determines the market value of one dollar of revenue by dividing the business capitalization by annual sales volume. This metric allows an investor to assess the degree of asset overheating and the risk of capital freeze during periods of structural transformation. By analyzing the dynamics of the capitalization-to-revenue ratio, one can observe the impact of regulatory barriers in China and high R&D costs. These factors constrain the profitability of Pheton Holdings Ltd. (PTHL), creating pressure on its fundamental valuation.

Karo sapa Pheton Holdings Ltd saingan

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals)|Rasio kapitalisasi pasar marang pendapatan BHST|Invizyne Technologies - Multiplikator P/S|oramed.com (ORMP) - Kapitalisasi marang pendapatan|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator P/S|Multiplikator P/S cumberlandpharma.com|Rasio rega marang pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Multiplikator rega marang pendapatan|Multiplikator P/S TELO (telomirpharma.com)|RANI - Kapitalisasi marang pendapatan|SNYR - Rasio rega marang pendapatan|rallybio.com - Kapitalisasi marang volume dodolan|LEXX: Multiplikator P/S|Kapitalisasi marang pendapatan Pulmatrix Inc|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)